Artivion (NYSE:AORT) Announces Earnings Results

Artivion (NYSE:AORT) released its quarterly earnings results on Thursday. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02, Zacks reports. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion updated its FY 2025 guidance to EPS.

Artivion Stock Performance

Shares of NYSE AORT traded up $1.03 during trading hours on Thursday, reaching $47.54. The stock had a trading volume of 738,685 shares, compared to its average volume of 433,157. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -113.20 and a beta of 1.67. Artivion has a twelve month low of $21.97 and a twelve month high of $47.69. The business’s fifty day moving average is $42.42 and its two-hundred day moving average is $35.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AORT shares. JMP Securities increased their target price on Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Wall Street Zen upgraded Artivion from a “hold” rating to a “buy” rating in a report on Monday, August 25th. Stifel Nicolaus increased their price objective on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, September 29th. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $32.00 to $38.80 in a research report on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $43.97.

Insider Buying and Selling at Artivion

In other news, SVP Jean F. Holloway sold 10,000 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the completion of the transaction, the senior vice president owned 172,129 shares in the company, valued at approximately $7,637,363.73. This represents a 5.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider John E. Davis sold 10,802 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the transaction, the insider directly owned 208,778 shares of the company’s stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 74,858 shares of company stock worth $3,250,129. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Sei Investments Co. bought a new position in shares of Artivion during the 2nd quarter worth approximately $1,627,000. Jane Street Group LLC bought a new stake in Artivion in the second quarter valued at $1,169,000. Thrivent Financial for Lutherans raised its stake in Artivion by 20.4% during the second quarter. Thrivent Financial for Lutherans now owns 33,366 shares of the company’s stock worth $1,038,000 after acquiring an additional 5,654 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Artivion by 7.3% during the second quarter. CANADA LIFE ASSURANCE Co now owns 33,165 shares of the company’s stock valued at $1,032,000 after acquiring an additional 2,253 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of Artivion by 76.8% during the second quarter. Marshall Wace LLP now owns 31,526 shares of the company’s stock valued at $980,000 after acquiring an additional 13,698 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.